SIWA Therapeutics Demonstrates Senescent Cell Clearing Antibody Inhibits Tumor Metastasis
Chicago IL — SIWA Therapeutics today reports results of its recent in vivo preclinical study which showed that its monoclonal antibody for removing senescent cells, SIWA 318, significantly inhibited tumor metastasis. Importantly, there were no observable adverse effects from the treatment and no increase in tumor growth over the control group.
“These results suggest that the removal of senescent cells may become a therapeutic approach against metastatic cancers,” said Lewis Gruber, co-founder and chief executive officer of SIWA Therapeutics. “Based on data we and the rest of the scientific community have generated over the last several years, the evidence is clearly mounting that senescent cells are causally implicated in the manifestation and progression of many diseases including cancer metastasis.”
The study was done in a BALBc 4T1 metastatic breast cancer mouse model. Mice were grouped to receive 5 ug/g, 10 ug/g, or saline injections two times daily for three weeks. A fourth group received no treatment. At 23 days, when the study ended, the 10ug/g group showed 30% (p < 0.001) fewer metastatic lung foci compared to the control.
The new data are consistent with earlier results in which we showed that SIWA 318 significantly increased muscle mass in normally aged CD-1 mice as well as significantly reducing the level of p16INK4a expression, a validated biomarker of senescent cells. Based on the results SIWA has generated to date, the Company is optimizing a humanized form of SIWA 318, and planning additional preclinical studies.
ABOUT SIWA Therapeutics
SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus is on certain rare and fast track diseases, including cancer metastasis and muscle wasting diseases, such as muscular dystrophy. Beyond these indications, senescent cells are causally implicated in a wide variety of diseases including: neurodegenerative diseases; autoimmune conditions, and infectious diseases. SIWA is currently optimizing its lead antibody, SIWA 318, and in parallel, seeking partnerships to advance SIWA 318 and other related technologies to broaden and accelerate its development pipeline. www.siwatherapeutics.com
Forward Looking Statements
Certain information contained in this press release represents or is based upon forward-looking statements or information. Forward-looking statements and information can be identified by the use of terms such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “continue” or “believe” or the negative thereof or other variations or comparable terminology. Such Forward-looking statements include statements regarding SIWA’s expectations concerning, among other things the ability to advance into clinical trials. Various factors may cause differences between SIWA’s expectations and actual results. Any forward-looking statements that are made in this press release speak only as of the date of this press release and SIWA assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.